Your browser doesn't support javascript.
loading
Essential Thrombocytosis in Patients <40 Years Old With Acute Coronary Syndromes: A Not So Uncommon Underlying Diagnosis Often Overlooked.
Kok, Lisa; Taverne, Laura F; Verbeek, Eva C; van de Wetering, Machiel; Voogel, Albertus J; Oosterom, Liane; Herrman, Jean-Paul R; Kuipers, Remko S.
Afiliación
  • Kok L; Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, NLD.
  • Taverne LF; Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, NLD.
  • Verbeek EC; Cardiothoracic Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, NLD.
  • van de Wetering M; Cardiology, BovenIJ Ziekenhuis, Amsterdam, NLD.
  • Voogel AJ; Cardiology, Spaarne Ziekenhuis, Haarlem, NLD.
  • Oosterom L; Cardiology, Dijklander Ziekenhuis Purmerend, Purmerend, NLD.
  • Herrman JR; Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, NLD.
  • Kuipers RS; Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, NLD.
Cureus ; 14(12): e32638, 2022 Dec.
Article en En | MEDLINE | ID: mdl-36654555
ABSTRACT

BACKGROUND:

In patients under <40 years, traditional cardiovascular (CV)-risk factors are a less likely cause of acute coronary syndromes (ACS) compared to older counterparts.

AIMS:

To estimate the prevalence of essential thrombocytosis (ET), a hematological disorder and less-prevalent risk factor, in young patients presenting with ACS.

METHODS:

We constructed a retrospective database of all patients <40 years (n=271) that had consecutively undergone coronary angiography (CAG) after their first ACS within our hospital within the last ten years (2010-2020) and had known thrombocyte counts (n=241). Patients with thrombocytes >450x10*9/L were screened for this hematological disorder.

RESULTS:

In our database, we identified 15 subjects with thrombocytosis. One was previously known as ET. Of the remaining 14 patients, five were considered reactive/secondary thrombocytosis, and four were lost to follow-up, four were eventually diagnosed with ET, one remains uncertain. The diagnosis was newly established before the initiation of this study in two patients (average delay six years). Two patients were identified as a result of this study. 

Conclusion:

With a prevalence of at least 2.1%, ET appears not uncommon in patients <40 years with ACS. Moreover, screening patients with ACS and elevated thrombocytes yielded a novel diagnosis of ET in 27% of patients. The diagnosis was initially missed in all cases. Since the timing of revascularization should be adjusted to thrombocyte count/initiation of ET therapy to prevent thrombotic complications, cardiologists should know, recognize and screen for this pathology in ACS-patients, notably in those with absent traditional CV-risk factors an 'ACS-protocol' aimed at less-prevalent risk factors could support this.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cureus Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cureus Año: 2022 Tipo del documento: Article